Brief: WntResearch provides update from ongoing phase 1b-study with Foxy-5

Opsy Holding AB

25/08/2016 13:01

Aug 25 (Reuters) - Wntresearch AB  WNT.ST : 
    * The phase 1b-study of Foxy-5 - a drug candidate for the prevention of metastasis - after 
approved safety evaluation at completed dose level three is now advancing to the next dosage 
level in Denmark 
    * Furthermore, dosage of patients has been able to commence in the UK, while the company has 
decided not to extend the trial to further study centres 
    * The Phase 1b-study with Foxy-5 is being undertaken in patients with advanced and 
metastasised colon, prostate or breast cancer who's primary tumour express no or low level 
Wnt-5a 
    * The primary purpose of the phase 1b-study is to create a solid basis for decision on which 
dosage levels that should be included in the coming phase 2 study that is expected to start 
during 2017   
 
 Source text: http://bit.ly/2biJqbv 
     
 Further company coverage:  WNT.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))